Company: OSRH
Filing Date: 2025-01-24
Form Type: S-4/A
Source: 0001213900-25-006139
Chunk: 285

Company: OSR Holdings, Inc.
Filing Date: 2025-01-24
Form: S-4/A
Chunk 285
---
.75 billion in 2020, and is estimated to reach $15.693 billion by 2030, growing at a CAGR of 8.8% from 2021 to 2030. 8 Alongside its review of the foregoing market data, the BLAC M&A Committee reviewed OSR Holdings’ asset pipeline which includes Vaximm’s drug candidates for recurrent GBM, hepatocellular cancer, metastatic colorectal cancer, and Darnatein’s drug candidate for osteoarthritis, and believes, based on each pipeline asset’s targeted therapy and the projected growth of the corresponding market, that OSR Holdings’ asset pipeline candidates have the fair market values ascribed to them by the valuation reports described in the section entitled “The Business Combination — The BLAC M&A Committee’s Reasons for the Approval of the Business Combination — Fair Market Value”which section contains a summary of the cash flow projections and detailed assumptions underlying the models in those reports. ____________ 5 https://www.futurewiseresearch.com/healthcare -market-research /Hepatocellular -Carcinoma -(HCC)/11543 6 https://www.giiresearch.com/report/mx1447722 -metastatic-colorectal-cancer-market-assessment-by .html 7Dekker, E., et al. (2019). “Colorectal cancer.” The Lancet, 394(10207), 1467 -1480 8 https://www.alliedmarketresearch.com/osteoarthritis -treatment-market-A12691 169 The BLAC M&A Committee considered the foregoing information, among the other information described herein, in its conclusion that the Business Combination is fair to, advisable, and in the best interests of BLAC and its stockholders. OSR Holdings’ Business Model The BLAC M&A Committee considered it noteworthy and meaningful from its due diligence standpoint that OSR Holdings operates a “Hub -and-Spoke” business model with a centralized portfolio management team of the holding company which owns and controls a growing portfolio of emerging biotech and medtech companies (in South Korea and Switzerland), as opposed to the traditional “single platform/single entity” biotech corporate model. OSR Holdings’ business objective is to optimize value creation for each of its product candidates and thereby continuously assess the best pathway for each, as it progresses through preclinical and clinical development processes, including through internal advancement, partnerships with established companies, and spin -outsor IPOs.